Chronic Lymphocytic Leukemia Clinical Trials in Durham, North Carolina

9 studies are recruiting for chronic lymphocytic leukemia in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymph…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Durham VA Medical Center, Durham, North Carolina
    Locations
    632 in total
    Run by
    National Cancer Institute (NCI)
  2. A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kin…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Duke University Medical Center, Durham, North Carolina
    Locations
    214 in total
    Run by
    BeOne Medicines
  3. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

    Stage
    Not phased
    Ages
    40 to 75
    Site
    Durham VA Medical Center, Durham, North Carolina
    Locations
    745 in total
    Run by
    Alliance for Clinical Trials in Oncology
  4. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhi…

    Stage
    Phase 3
    Ages
    65 and older
    Site
    Duke University Medical Center, Durham, North Carolina
    Locations
    210 in total
    Run by
    Alliance for Clinical Trials in Oncology
  5. A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

    The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studie…

    Stage
    Phase 4
    Ages
    18 and older
    Site
    Duke University Medical Center, Durham, North Carolina
    Locations
    38 in total
    Run by
    Eli Lilly and Company
  6. A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

    Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned stu…

    Stage
    Phase 4
    Ages
    18 and older
    Site
    Duke University Medical Center, Durham, North Carolina
    Locations
    36 in total
    Run by
    Eli Lilly and Company
  7. Study of SGR-1505 in Mature B-Cell Neoplasms

    The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Duke University, Durham, North Carolina
    Locations
    36 in total
    Run by
    Schrödinger, Inc.
  8. AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

    This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Duke University, Durham, North Carolina
    Locations
    13 in total
    Run by
    Carna Biosciences, Inc.
  9. A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. This type of pill is called "Bruton Tyrosine Kinase Inhibitor" or BTKi. Another treatment for CLL/SLL is …

    Stage
    Phase 2
    Ages
    18 to 80
    Site
    Durham VA Medical Center, Durham, NC, Durham, North Carolina
    Locations
    4 in total
    Run by
    VA Office of Research and Development

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.